FY2029 Earnings Estimate for ABVX Issued By Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX - Free Report) - Leerink Partnrs issued their FY2029 earnings estimates for ABIVAX Société Anonyme in a research note issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme's current full-year earnings is ($2.88) per share.

ABVX has been the topic of a number of other reports. JMP Securities reissued a "market outperform" rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a report on Wednesday, December 4th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $38.67.

ABIVAX Société Anonyme Price Performance

Shares of NASDAQ:ABVX traded up $0.33 during midday trading on Thursday, hitting $6.63. The stock had a trading volume of 83,315 shares, compared to its average volume of 158,105. The company's 50-day moving average price is $7.03 and its 200-day moving average price is $9.45. ABIVAX Société Anonyme has a fifty-two week low of $5.49 and a fifty-two week high of $17.02.

Institutional Trading of ABIVAX Société Anonyme

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. boosted its holdings in shares of ABIVAX Société Anonyme by 28.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after acquiring an additional 119,300 shares in the last quarter. abrdn plc raised its position in ABIVAX Société Anonyme by 34.1% in the fourth quarter. abrdn plc now owns 424,181 shares of the company's stock valued at $3,105,000 after purchasing an additional 107,750 shares during the last quarter. Walleye Capital LLC raised its position in ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock valued at $2,965,000 after purchasing an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock valued at $150,000 after purchasing an additional 5,900 shares in the last quarter. Finally, R Squared Ltd bought a new stake in shares of ABIVAX Société Anonyme during the fourth quarter worth about $36,000. Institutional investors own 47.91% of the company's stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.